Jeffrey Evans

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Ruth Plummer, Christopher J. Jones, Mark R. Middleton et al. · Clinical Cancer Research · 2008 · 384 citations · Full text

Medicine, Oncology, Pharmacology +15

First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors

Ruth Plummer, Mark R. Middleton, R. Wilson et al. · Journal of Clinical Oncology · 2005 · 44 citations

Medicine, Oncology, Pharmacology +13

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Luis de la Cruz‐Merino, Lorenza Di Guardo, Jean‐Jacques Grob et al. · Journal of Translational Medicine · 2017 · 44 citations · Full text

Medicine, Oncology, Ophthalmology +14

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

Claire L. Mitchell, James P.B. O’Connor, Caleb Roberts et al. · Cancer Chemotherapy and Pharmacology · 2010 · 24 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Víctor Moreno, David Olmos, Carlos Gomez‐Roca et al. · Clinical Cancer Research · 2014 · 19 citations

Medicine, Oncology, Pharmacology +8